141 related articles for article (PubMed ID: 38629255)
1. Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial.
Li R; Li X; You X; Su M; Liu Y; Ke N; Cao D
Cancer Med; 2024 Apr; 13(8):e7131. PubMed ID: 38629255
[TBL] [Abstract][Full Text] [Related]
2. Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies.
Li J; Cheng Y; Bai C; Xu J; Shen L; Li J; Zhou Z; Li Z; Chi Y; Yu X; Li E; Xu N; Liu T; Lou W; Bai Y; Yuan X; Wang X; Yuan Y; Chen J; Guan S; Fan S; Su W
ESMO Open; 2022 Apr; 7(2):100453. PubMed ID: 35344750
[TBL] [Abstract][Full Text] [Related]
3. Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.
Zhang P; Shi S; Xu J; Chen Z; Song L; Zhang X; Cheng Y; Zhang Y; Ye F; Li Z; Yin F; Ji D; Gao H; Li Y; Chen W; Yang M; Weng D; Wu C; Ma Y; Sheng W; Zhao Y; Yin X; Shen W; Su W; Shi M; Fan S; Tan P; Xu Q; Lu M; Shen L
Eur J Cancer; 2024 Mar; 199():113539. PubMed ID: 38237373
[TBL] [Abstract][Full Text] [Related]
4. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J; Shen L; Zhou Z; Li J; Bai C; Chi Y; Li Z; Xu N; Li E; Liu T; Bai Y; Yuan Y; Li X; Wang X; Chen J; Ying J; Yu X; Qin S; Yuan X; Zhang T; Deng Y; Xiu D; Cheng Y; Tao M; Jia R; Wang W; Li J; Fan S; Peng M; Su W
Lancet Oncol; 2020 Nov; 21(11):1500-1512. PubMed ID: 32966811
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and meta-analysis.
Ali MA; Shah SS; Tahir N; Rehman S; Saeed M; Bajwa SF; Ali R; Aiman W; Anwar MY
J Neuroendocrinol; 2022 Jul; 34(7):e13149. PubMed ID: 35665971
[TBL] [Abstract][Full Text] [Related]
6. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J; Shen L; Bai C; Wang W; Li J; Yu X; Li Z; Li E; Yuan X; Chi Y; Yin Y; Lou W; Xu N; Bai Y; Zhang T; Xiu D; Wang X; Yuan Y; Chen J; Qin S; Jia R; Lu M; Cheng Y; Zhou Z; Li J; He J; Su W
Lancet Oncol; 2020 Nov; 21(11):1489-1499. PubMed ID: 32966810
[TBL] [Abstract][Full Text] [Related]
7. Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
Xu J; Li J; Bai C; Xu N; Zhou Z; Li Z; Zhou C; Jia R; Lu M; Cheng Y; Mao C; Wang W; Cheng K; Su C; Hua Y; Qi C; Li J; Wang W; Li K; Sun Q; Ren Y; Su W
Clin Cancer Res; 2019 Jun; 25(12):3486-3494. PubMed ID: 30833272
[TBL] [Abstract][Full Text] [Related]
8. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
[No Abstract] [Full Text] [Related]
9. Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep).
Li J; Cheng Y; Bai C; Xu J; Shen L; Li J; Zhou Z; Li Z; Chi Y; Yu X; Li E; Xu N; Liu T; Lou W; Bai Y; Yuan X; Wang X; Yuan Y; Chen J; Guan S; Fan S; Su W
Eur J Cancer; 2022 Jul; 169():1-9. PubMed ID: 35489301
[TBL] [Abstract][Full Text] [Related]
10. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors.
Lu X; Yan S; Koral KA; Chen Z
Expert Rev Anticancer Ther; 2021 Sep; 21(9):917-926. PubMed ID: 34142932
[No Abstract] [Full Text] [Related]
11. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.
Fiore F; Del Prete M; Franco R; Marotta V; Ramundo V; Marciello F; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A
Endocrine; 2014 Sep; 47(1):177-82. PubMed ID: 24385266
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Invariant Natural Killer T Cell Infusion Plus Transarterial Embolization vs Transarterial Embolization Alone for Hepatocellular Carcinoma Patients: A Phase 2 Randomized Clinical Trial.
Guo J; Bao X; Liu F; Guo J; Wu Y; Xiong F; Lu J
J Hepatocell Carcinoma; 2023; 10():1379-1388. PubMed ID: 37637501
[TBL] [Abstract][Full Text] [Related]
13. A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
Xu J; Bai Y; Sun H; Bai C; Jia R; Li Y; Zhang W; Liu L; Huang C; Guan M; Zhou J; Su W
Cancer; 2021 Nov; 127(21):3975-3984. PubMed ID: 34355801
[TBL] [Abstract][Full Text] [Related]
14. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
Chen JX; Wileyto EP; Soulen MC
Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
[TBL] [Abstract][Full Text] [Related]
15. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.
Strosberg JR; Weber JM; Choi J; Campos TL; Valone TL; Han G; Schell MJ; Kvols LK
Ann Oncol; 2012 Sep; 23(9):2335-2341. PubMed ID: 22317769
[TBL] [Abstract][Full Text] [Related]
16. Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis.
Walter MA; Nesti C; Spanjol M; Kollár A; Bütikofer L; Gloy VL; Dumont RA; Seiler CA; Christ ER; Radojewski P; Briel M; Kaderli RM
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013700. PubMed ID: 34822169
[TBL] [Abstract][Full Text] [Related]
17. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F; Brizzi MP; Amoroso V; Giuffrida D; Panzuto F; Campana D; Prinzi N; Milione M; Cascella T; Spreafico C; Randon G; Oldani S; Leporati R; Scotto G; Pulice I; Stocchetti BL; Porcu L; Coppa J; Di Bartolomeo M; de Braud F; Pusceddu S
BMC Cancer; 2023 Sep; 23(1):908. PubMed ID: 37752423
[TBL] [Abstract][Full Text] [Related]
18. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Dasari A; Hamilton EP; Falchook GS; Wang JS; Li D; Sung MW; Chien C; Nanda S; Tucci C; Hahka-Kemppinen M; Paulson AS
Invest New Drugs; 2023 Jun; 41(3):421-430. PubMed ID: 37074571
[TBL] [Abstract][Full Text] [Related]
19. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden.
Liu Y; Liu H; Chen W; Yu H; Yao W; Fan W; Li J; Chen M; Chen J; Wang Y
Cancer Med; 2022 Jul; 11(13):2588-2600. PubMed ID: 35289113
[TBL] [Abstract][Full Text] [Related]
20. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]